mchedester
Long

Biocept - Buy the negativity. The revenue doesn't mind.

NASDAQ:BIOC   BIOCEPT INC
23 1 0
Biocept             has the best-in-breed liquid biopsy testing in the Immuno-Oncology space. Market cap is 70 million, but it's going to be several billion in a few years if they don't get bought out first.

Revenue in the second quarter ended 6/30/2016 increased 8 fold to 663,000 from 77,000 last year. This revenue only included half of June for their commerical launch of its PD-L1 protein expression test in mid-June. Frankly, I’m surprised that they didn’t burn through a lot more cash and issue a lot more shares considering their disastrous dilution last year. Their expenses didn’t go up as much as I was expecting either, and they’re sitting on $3.8 million in cash.
I usually don't buy microcaps, but this isn't going to be a microcap for long. GLTA
Reply
United States
United Kingdom
India
Deutschland
España
France
Italia
Polska
Brasil
Россия
Türkiye
Indonesia
Malaysia
日本
한국
简体
繁體
Home Stock Screener Forex Signal Finder Cryptocurrency Signal Finder Economic Calendar How It Works Chart Features House Rules Moderators Website & Broker Solutions Widgets Stock Charting Library Priority Support Feature Request Blog & News FAQ Help & Wiki Twitter
Profile Profile Settings Account and Billing Priority Support Ideas Published Followers Following Private Messages Chat Sign Out